Twist Bioscience (NASDAQ:TWST) Insider Dennis Cho Sells 9,514 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 9,514 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares in the company, valued at approximately $12,048,466.32. The trade was a 12.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Monday, September 21st, Dennis Cho sold 348 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total value of $57,590.52.
• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The shares were sold at an average price of $122.62, for a total value of $50,519.44.

Twist Bioscience Trading Up 8.7%

Shares of Twist Bioscience stock traded up $16.33 during mid-day trading on Monday, hitting $205.00. 3,203,579 shares of the stock were exchanged, compared to its average volume of 1,622,926. The stock has a market capitalization of $12.86 billion, a price-to-earnings ratio of -92.34 and a beta of 2.19. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $207.90. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $136.40 and a 200 day simple moving average of $92.42.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter in the previous year, the company posted $0.33 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. Research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on TWST shares. Robert W. Baird upped their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Canaccord Genuity Group boosted their price target on Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Piper Sandler raised their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. Guggenheim lifted their price objective on Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Leerink Partners boosted their target price on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $115.27.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Twist Bioscience during the 2nd quarter valued at $600,191,000. William Blair Investment Management LLC purchased a new stake in shares of Twist Bioscience during the second quarter valued at approximately $223,722,000. Bank of America Corp DE purchased a new stake in Twist Bioscience during the 2nd quarter worth $94,922,000. Allspring Global Investments Holdings LLC purchased a new position in Twist Bioscience in the 1st quarter valued at about $22,563,000. Finally, BNP Paribas Financial Markets increased its position in shares of Twist Bioscience by 242.2% during the fourth quarter. BNP Paribas Financial Markets now owns 415,609 shares of the company’s stock worth $13,183,000 after acquiring an additional 294,144 shares during the last quarter.

Twist Bioscience News Roundup

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience reported approximately 23% year-over-year revenue growth in its latest quarter, reinforcing the company’s expansion narrative and helping support bullish sentiment. Twist Bioscience stock reports 23 percent revenue growth
• Positive Sentiment: Leerink raised its price target for TWST from $120 to $160, signaling improved analyst expectations. Although the revised target remains below the recent share price, the increase may have added to buying momentum. Leerink raises target for Twist Bioscience stock
• Positive Sentiment: The stock reached a new 52-week high, reflecting strong momentum and investor demand. TWST has benefited from enthusiasm around biotechnology and synthetic-DNA markets, as well as attention from actively managed biotech funds. Twist Bioscience reaches new 52-week high
• Neutral Sentiment: CEO Emily Leproust, CFO Adam Laponis, CAO Robert Werner, SVP Paula Green and insider Dennis Cho sold shares primarily to cover tax withholding tied to vested equity awards. The transactions totaled roughly $14.3 million, but the CEO’s sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their usefulness as a signal of deteriorating business prospects. Twist Bioscience insider transaction filing
• Negative Sentiment: Valuation and profitability remain risks: the company continues to report net losses, and its latest quarterly earnings per share missed estimates despite beating revenue expectations. The sharp rally also leaves the stock well above Leerink’s revised target, increasing the potential for volatility or profit-taking.

Twist Bioscience Company Profile

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.